Former FDA Commissioner Scott Gottlieb said that late-stage coronavirus vaccine trials currently underway in the US are unlikely to have gathered enough evidence to receive emergency approval ahead of the November presidential election, reported CNBC.
"I think it's more likely you're going to get a top-line result some point in November and maybe be able to make a decision about an emergency use authorization after that," he added.
"If the vaccines are very effective at preventing CoOVID-19 disease, probably 70% to 80% effective based on how the trials are powered, you could get a readout at some point in October, a sort of top-line readout," he said, "but it's more likely that you're going to get a readout from those trials in November."
Gottlieb suggested that the only circumstance in which a vaccine trial could offer sufficient effectiveness data in October would be if the US coronavirus outbreak is "very dense" in terms of transmission rates throughout the general population, and the vaccines prove to be "very effective" in those in trials.
To read more NewsPoints articles, click here.